Using peptides to treat lung fibrosis
Peptides for the treatment of pulmonary fibrosis
This study is looking at a new treatment using special proteins from collagen to help people with severe lung scarring caused by pulmonary fibrosis, hoping to improve their lung function and overall health.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical University of South Carolina NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10990625 on NIH RePORTER |
What this research studies
This research investigates the use of peptides derived from collagen XVIII to treat pulmonary fibrosis, a serious condition that leads to lung scarring and failure. The approach focuses on the anti-fibrotic effects of these peptides, which have shown promise in pre-clinical models. By testing these peptides in patients with severe lung fibrosis, the research aims to provide a new therapeutic option that could potentially improve outcomes for those who currently have limited treatment options. The study will evaluate the effectiveness of these peptides in reducing fibrosis and improving lung function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary fibrosis, particularly those with end-stage disease who may be considering lung transplantation.
Not a fit: Patients with early-stage pulmonary fibrosis or those whose condition is not primarily fibrotic may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option for patients suffering from pulmonary fibrosis, potentially improving their quality of life and survival rates.
How similar studies have performed: While the use of peptides for treating fibrosis is a novel approach, there have been successful applications of peptide therapies in other fibrotic conditions, suggesting potential for success in this area as well.
Where this research is happening
Charleston, United States
- Medical University of South Carolina — Charleston, United States (Active)
Researchers
- Principal investigator: Feghali-Bostwick, Carol a. — Medical University of South Carolina
- Study coordinator: Feghali-Bostwick, Carol a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.